tradingkey.logo

Artivion Inc

AORT
查看詳細走勢圖
39.590USD
+0.120+0.30%
收盤 02/06, 16:00美東報價延遲15分鐘
1.88B總市值
虧損本益比TTM

Artivion Inc

39.590
+0.120+0.30%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.30%

5天

-2.89%

1月

-12.12%

6月

+21.07%

今年開始到現在

-13.20%

1年

+29.59%

查看詳細走勢圖

TradingKey Artivion Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Artivion Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名13/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為51.71。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Artivion Inc評分

相關信息

行業排名
13 / 205
全市場排名
84 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Artivion Inc亮點

亮點風險
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
業績高增長
公司營業收入穩步增長,連續3年增長23.82%
估值低估
公司最新PE估值-171.75,處於3年歷史低位
機構加倉
最新機構持股43.29M股,環比增加0.07%
喬爾·格林布拉特持倉
明星投資者喬爾·格林布拉特持倉,最新持倉14.72K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.99

分析師目標

基於 7 分析師
買入
評級
51.714
目標均價
+29.06%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Artivion Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Artivion Inc簡介

Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
公司代碼AORT
公司Artivion Inc
CEOMackin (James Patrick)
網址https://artivion.com/
KeyAI